Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063906
Chunk: 356

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 356
---
 although many of these state laws apply where a claim is submitted to any third -partypayor and not merely a governmental payor program. In Europe various countries have adopted anti -briberylaws providing for severe consequences, in the form of criminal penalties and/or significant fines, for individuals and/or companies committing a bribery offence. Violations of these anti -briberylaws, or allegations of such violations, could have a negative impact on DiamiR’s business, results of operations and reputation. Properties DiamiR acquired a CLIA certified, CAP accredited laboratory space in New Haven CT in April 2021. DiamiR operates this lab with DiamiR employees and pays a monthly fee of $3,565 for its rent. While DiamiR believes that its current laboratory is adequate to meet its near term objectives, DiamiR may need additional space for laboratory operations in the future, and may look to expand its current lab, or invest in a developing a larger facility as DiamiR’s needs evolve. 216

DIAMIR’S DIRECTORS, OFFICERS AND CORPORATE MANAGEMENT Directors and Executive Officers The table below lists Diamir’s officers and directors.

| Name                |     | Age |     | Position                                    |
| Alidad Mireskandari |     |  57 |     | Chief Executive Officer                     |
| Kira S. Sheinerman  |     |  55 |     | Executive Director, Secretary and Treasurer |
| Gary Anthony        |     |  63 |     | Chief Financial Officer                     |

Alidad Mireskandari, Ph.D., MBA, Chief Executive Officer.Dr. Mireskandari joined DiamiR in July 2022, and has over 12 years of life sciences industry experience with a focus on molecular diagnostic test development and commercialization, including regulatory and reimbursement expertise. Dr. Mireskandari most recently served as Chief Development Officer of Interpace Biosciences from 2013 to 2022, and prior to that as President & CEO of JS Genetics from 2009 to 2013. From 2000 to 2009, Dr. Mireskandari was a hedge fund manager in charge of Life Sciences trading portfolios of Nomura Securities, BNP Paribas and Raeburn Advisors. Prior to this experience, he was a consultant with PRTM’s life sciences industry group from 1998 to 2000 and a research fellow at National Institutes of Health